Ezetimibe vs. PCSK9 Inhibitor: Which Add-On First After a Recent NSTEMI
Six weeks post-NSTEMI, LDL 92 on high-intensity statin, goal under 55. The guideline sequence says try the cheap oral pill first — the question is whether that sequence costs real risk-days in exactly the window where risk is highest.
F.N., a 63-year-old man, has worked as a commercial fisherman for nearly forty years, still taking two- to three-week trips out on the boat several times a season, work he has no plan to trade for something easier ashore. Six weeks ago, midway through a trip, he developed chest pressure that didn't resolve, and the boat turned back early enough for him to reach a hospital and be diagnosed with an NSTEMI — his first cardiac event, culprit lesion in the right coronary artery, treated with a drug-eluting stent. He was discharged on atorvastatin 80mg, the first lipid-lowering therapy he had ever taken; his pre-treatment LDL, drawn on admission, was 165 mg/dL. At today's six-week follow-up, his LDL has fallen to 92 mg/dL on the statin alone — a real 44% reduction — but remains well above the under-55 goal that applies to him as a very-high-risk secondary-prevention patient in the weeks immediately following an ACS event.
Ezetimibe and PCSK9 inhibitors both lower LDL further on top of a statin, but by different mechanisms and to different degrees. Ezetimibe blocks intestinal cholesterol absorption, typically adding another 20% to 25% reduction — modest, but IMPROVE-IT already established a real outcome benefit from that reduction on top of statin therapy. PCSK9 inhibitors are monoclonal antibodies that bind PCSK9, the circulating protein that latches onto LDL receptors and routes them to lysosomal degradation; blocking it lets those receptors recycle, producing a much larger reduction, 50% to 60%. The trial that speaks most directly to F.N. is ODYSSEY OUTCOMES, which enrolled nearly 19,000 patients one to twelve months after an ACS event and found alirocumab reduced major cardiovascular events. FOURIER, the other large PCSK9 outcomes trial, studied stable atherosclerotic disease rather than recent ACS, and its benefit grew with exposure — about 16% in the first year and 25% beyond twelve months — so it argues for starting early and staying on, not for a benefit that lands within weeks. The 2018 cholesterol guideline and the 2022 ACC pathway both describe a stepwise sequence — ezetimibe first, recheck in four to six weeks, escalate to a PCSK9 inhibitor only if still above goal — built on cost, access, and the practical reality that PCSK9 inhibitors are injectable and often require prior authorization.
Cardiology follow-up, six weeks post-discharge
I'd start a PCSK9 inhibitor today, skip the stepwise ezetimibe trial. ODYSSEY OUTCOMES tested this drug class in exactly his population — patients one to twelve months out from an ACS — and found real event reduction, and his residual risk is highest right now, in the weeks right after his event. That's the window a stepwise delay actually costs. A PCSK9 inhibitor gets him to goal in one step at a magnitude ezetimibe alone likely won't reach anyway.
I'm not saying the guideline sequence is wrong in general — I'm saying the early post-ACS window is exactly where its usual logic is weakest.
IMPROVE-IT already proved ezetimibe's own outcome benefit on top of statin therapy — it isn't a placeholder step, it's a proven one. Committing him to an injectable, prior-authorization-heavy therapy before establishing that ezetimibe alone won't get him there isn't excess caution, it's the actual evidence-based sequence both major guidelines recommend for exactly this situation.
I take the early-risk-window point seriously — I just don't think four to six weeks of a real, proven interim therapy is the same as leaving him untreated during that window.
There's a practical piece neither of you has weighed yet. He's at sea for weeks at a stretch with limited pharmacy access — a daily oral pill he can carry in a duffel bag is a therapy he'll actually take reliably, compared to an injectable that needs refrigeration and a set dosing interval he'd have to manage offshore. That's not a medical argument for one drug over the other — it's a reason to start with the one he's most likely to actually stay on.
Agreed: start ezetimibe 10mg daily today, continue atorvastatin 80mg unchanged, and recheck LDL in six weeks with an explicit, pre-committed plan to start a PCSK9 inhibitor immediately if he remains above the under-55 goal — not a passive reassessment.
Not agreed, and carried forward explicitly rather than smoothed over:
All three voices agreed a PCSK9 inhibitor starts without further delay — the Preventive Cardiologist's original preference for starting today would then read as the six-week delay having cost real risk-time for no clinical benefit.
The Clinical Pharmacologist's and Primary Care Physician's sequencing is validated for this patient, though the Preventive Cardiologist noted this would be one case, not evidence the early- window argument was wrong in general.
The Preventive Cardiologist maintained, even after agreeing to today's plan, that the early post-ACS window is where the standard stepwise sequence is weakest — accepted as this patient's plan, not as a retraction of that broader concern.